Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
l-2-Hydroxyglutarate remodeling of the epigenome and epitranscriptome creates a metabolic vulnerability in kidney cancer models.
Kundu A, Brinkley GJ, Nam H, Karki S, Kirkman R, Pandit M, Shim E, Widden H, Liu J, Heidarian Y, Mahmoudzadeh NH, Fitt AJ, Absher D, Ding HF, Crossman DK, Placzek WJ, Locasale JW, Rakheja D, McConathy JE, Ramachandran R, Bae S, Tennessen JM, Sudarshan S. Kundu A, et al. Among authors: kirkman r. J Clin Invest. 2024 May 14;134(13):e171294. doi: 10.1172/JCI171294. J Clin Invest. 2024. PMID: 38743486 Free PMC article.
Teleological role of L-2-hydroxyglutarate dehydrogenase in the kidney.
Brinkley G, Nam H, Shim E, Kirkman R, Kundu A, Karki S, Heidarian Y, Tennessen JM, Liu J, Locasale JW, Guo T, Wei S, Gordetsky J, Johnson-Pais TL, Absher D, Rakheja D, Challa AK, Sudarshan S. Brinkley G, et al. Among authors: kirkman r. Dis Model Mech. 2020 Nov 27;13(11):dmm045898. doi: 10.1242/dmm.045898. Dis Model Mech. 2020. PMID: 32928875 Free PMC article.
Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer.
Shelar S, Shim EH, Brinkley GJ, Kundu A, Carobbio F, Poston T, Tan J, Parekh V, Benson D, Crossman DK, Buckhaults PJ, Rakheja D, Kirkman R, Sato Y, Ogawa S, Dutta S, Velu SE, Emberley E, Pan A, Chen J, Huang T, Absher D, Becker A, Kunick C, Sudarshan S. Shelar S, et al. Among authors: kirkman r. Clin Cancer Res. 2018 Dec 15;24(24):6433-6446. doi: 10.1158/1078-0432.CCR-18-1727. Epub 2018 Aug 14. Clin Cancer Res. 2018. PMID: 30108105 Free PMC article.
The TGF-β/HDAC7 axis suppresses TCA cycle metabolism in renal cancer.
Nam H, Kundu A, Karki S, Brinkley GJ, Chandrashekar DS, Kirkman RL, Liu J, Liberti MV, Locasale JW, Mitchell T, Varambally S, Sudarshan S. Nam H, et al. Among authors: kirkman rl. JCI Insight. 2021 Nov 22;6(22):e148438. doi: 10.1172/jci.insight.148438. JCI Insight. 2021. PMID: 34609963 Free PMC article.
L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer.
Shim EH, Livi CB, Rakheja D, Tan J, Benson D, Parekh V, Kho EY, Ghosh AP, Kirkman R, Velu S, Dutta S, Chenna B, Rea SL, Mishur RJ, Li Q, Johnson-Pais TL, Guo L, Bae S, Wei S, Block K, Sudarshan S. Shim EH, et al. Among authors: kirkman r. Cancer Discov. 2014 Nov;4(11):1290-8. doi: 10.1158/2159-8290.CD-13-0696. Epub 2014 Sep 2. Cancer Discov. 2014. PMID: 25182153 Free PMC article.
PRDM16 suppresses HIF-targeted gene expression in kidney cancer.
Kundu A, Nam H, Shelar S, Chandrashekar DS, Brinkley G, Karki S, Mitchell T, Livi CB, Buckhaults P, Kirkman R, Tang Y, Rowe GC, Wei S, Varambally S, Sudarshan S. Kundu A, et al. Among authors: kirkman r. J Exp Med. 2020 Jun 1;217(6):e20191005. doi: 10.1084/jem.20191005. J Exp Med. 2020. PMID: 32251515 Free PMC article.
PGC1α suppresses kidney cancer progression by inhibiting collagen-induced SNAIL expression.
Nam H, Kundu A, Brinkley GJ, Chandrashekar DS, Kirkman RL, Chakravarthi BVSK, Orlandella RM, Norian LA, Sonpavde G, Ghatalia P, Fei F, Wei S, Varambally S, Sudarshan S. Nam H, et al. Among authors: kirkman rl. Matrix Biol. 2020 Jul;89:43-58. doi: 10.1016/j.matbio.2020.01.001. Epub 2020 Jan 23. Matrix Biol. 2020. PMID: 31982456 Free PMC article.
Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP, Marshall CB, Coric T, Shim EH, Kirkman R, Ballestas ME, Ikura M, Bjornsti MA, Sudarshan S. Ghosh AP, et al. Among authors: kirkman r. Oncotarget. 2015 Jul 20;6(20):17895-910. doi: 10.18632/oncotarget.4963. Oncotarget. 2015. PMID: 26255626 Free PMC article.
142 results